KPV is one of the most searched peptides that almost nobody has studied in people. The name is the molecule: lysine, proline and valine, three amino acids in a row. They are the tail end of alpha-melanocyte-stimulating hormone, which is why papers often write it as alpha-MSH(11-13). This page covers what the research actually found, in what, and what has never been done. It sits under the recovery goal.
What KPV is
Alpha-MSH is a hormone with a long history in inflammation research. KPV is its final fragment, and the interest in it comes from a simple observation: the fragment appears to keep much of the parent hormone's anti-inflammatory behavior while being far smaller and easier to deliver.
What the cell studies found
The most cited work is a 2008 paper in Gastroenterology [1]. It used two human intestinal epithelial cell lines, Caco2-BBE and HT29-Cl.19A, plus Jurkat cells, a human T-cell line. The cells were stimulated with pro-inflammatory cytokines with and without KPV.
At nanomolar concentrations, KPV inhibited activation of the NF-kappaB and MAP kinase signaling pathways and reduced pro-inflammatory cytokine secretion. The same paper identified how it gets in: PepT1, a transporter that carries di- and tripeptides, normally found in the small intestine and switched on in the colon during inflammatory bowel disease. That transporter detail matters, because it explains why a peptide swallowed rather than injected might reach inflamed tissue at all.
A 2025 paper extended the same signaling story to skin [3]. It exposed HaCaT cells, a human keratinocyte line, to fine particulate matter and reported that KPV reduced the resulting apoptosis and inflammation through the same MAPK and NF-kappaB pathways.
What the animal studies found
The 2008 Gastroenterology paper also ran two mouse models of colitis, one induced with dextran sodium sulfate and one with TNBS [1]. KPV was added to the animals’ drinking water. It reduced the incidence of colitis in both, measured by tissue appearance under the microscope and by pro-inflammatory cytokine expression.
A second 2008 paper, in Inflammatory Bowel Disease, tested KPV in dextran sodium sulfate colitis and in a transfer colitis model [2]. Treated mice recovered earlier and regained significantly more body weight. Inflammatory infiltrates in the colon were significantly reduced, as was myeloperoxidase activity, a marker of neutrophil presence.
That paper included one result worth singling out. It repeated the experiment in mice engineered to carry a non-functional melanocortin-1 receptor, the receptor the parent hormone acts through. KPV treatment rescued every animal in that group from death during colitis. The effect therefore does not appear to depend on the receptor its parent hormone uses, which is part of why the fragment is studied separately.
Why delivery is the hard part
A tripeptide swallowed on its own has a short life. A 2010 paper in Gastroenterology built 400 nanometer particles loaded with KPV, wrapped them in an alginate and chitosan gel designed to collapse in the colon, and tested them in the same dextran sodium sulfate colitis model [3]. Mice given the loaded particles were protected on inflammatory and histologic measures against mice given the colitis agent alone.
The number that paper reports is the interesting one. Packaged this way, KPV produced similar therapeutic effect at a concentration 12,000-fold lower than the same peptide in free solution. That is a statement about delivery rather than about potency, and it is the clearest reason to treat an unformulated tripeptide and a targeted one as different propositions.
What has never been done
No clinical trial has tested KPV in people. ClinicalTrials.gov returns no study at all with KPV as an intervention. Searching the published literature the same way returns cell and animal work, and the records that carry a human tag are human cell lines rather than human participants.
So the honest summary is narrow. There is a consistent, repeated anti-inflammatory signal across cell lines and two mouse colitis models, produced by more than one laboratory. There is no evidence about what KPV does in a human body, because that experiment has not been published.
Where it stands with the FDA
KPV appears on neither of the FDA’s bulk drug substance lists: not in the 503A categories, updated May 14, 2026, and not in the 503B categories, updated March 21, 2025. A compounding pharmacy therefore has no lawful route to prepare it.
The FDA's compounding advisory committee did vote in July 2026 in favor of listing it, by eight to six with one abstention. That vote is a recommendation. It does not bind the agency, and pharmacies may not compound the substance until final rulemaking is in place. Anything sold as KPV today sits outside that route, which is a separate question from whether the laboratory findings are interesting.
For how that framework works in general, see what makes a peptide legal to prescribe, and for two other compounds in the same position, BPC-157 and TB-500. The wider question of what inflammation-targeted peptides can and cannot do is covered in peptides for inflammation.